William L Hwang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9343064/publications.pdf

Version: 2024-02-01

42 papers

2,575 citations

331670 21 h-index 32 g-index

44 all docs

44 docs citations

44 times ranked

3605 citing authors

#	Article	IF	Citations
1	Spatially defined enrichment of a neuronal-like malignant phenotype in pancreatic cancer after neoadjuvant treatment Journal of Clinical Oncology, 2022, 40, 610-610.	1.6	0
2	Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. Lancet Oncology, The, 2022, 23, e62-e74.	10.7	36
3	DNA repair and immune checkpoint blockade response. Cancer Genetics, 2022, 264-265, 1-4.	0.4	0
4	Abstract SY12-04: Multicellular spatial community featuring a novel neuronal-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy. Cancer Research, 2022, 82, SY12-04-SY12-04.	0.9	0
5	Severe lymphopenia predicts poorer survival in patients with rectal cancer undergoing neoadjuvant chemoradiation Journal of Clinical Oncology, 2021, 39, 138-138.	1.6	0
6	Prognostic impact of chemoradiation-related lymphopenia in patients with locally advanced pancreatic cancer Journal of Clinical Oncology, 2021, 39, 439-439.	1.6	0
7	Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. Clinical Cancer Research, 2021, 27, 2807-2815.	7.0	12
8	Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. Clinical Cancer Research, 2021, 27, 3825-3833.	7.0	8
9	Abstract 94: Multi-compartment reprogramming and spatially-resolved interactions in frozen pancreatic cancer with and without neoadjuvant chemotherapy and radiotherapy at single-cell resolution., 2021,,.		0
10	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell, 2021, 39, 1342-1360.e14.	16.8	119
11	Antigen dominance hierarchies shape TCF1+ progenitor CD8 TÂcell phenotypes in tumors. Cell, 2021, 184, 4996-5014.e26.	28.9	84
12	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ TÂcells in tumor-draining lymph nodes. Immunity, 2021, 54, 2338-2353.e6.	14.3	111
13	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genetics, 2021, 258-259, 61-68.	0.4	2
14	Abstract PR-006: Integrative genomic characterization of therapeutic targets for pancreatic cancer. , 2021, , .		0
15	Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model. Radiotherapy and Oncology, 2020, 142, 154-161.	0.6	30
16	Silver Linings: An Opportunity to Improve Clinical Paradigms After the COVID-19 Pandemic. JCO Oncology Practice, 2020, 16, 532-534.	2.9	0
17	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Ca-A Cancer Journal for Clinicians, 2020, 70, 375-403.	329.8	237
18	Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases. Journal of Neuro-Oncology, 2020, 148, 81-88.	2.9	5

#	Article	IF	CITATIONS
19	Outcomes of HPV-Associated Squamous Cell Carcinoma of the Head and Neck: Impact of Race and Socioeconomic Status. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 177-184.	4.9	16
20	Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study. Oral Oncology, 2019, 98, 28-34.	1.5	12
21	Sex Disparity and Copy Number Alterations in Esophageal Squamous Cell Carcinoma. Clinical Gastroenterology and Hepatology, 2019, 17, 1207-1209.	4.4	5
22	Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer, 2019, 125, 1357-1364.	4.1	18
23	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncology, 2018, 4, e175230.	7.1	65
24	Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. Advanced Drug Delivery Reviews, 2018, 125, 122-131.	13.7	21
25	Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. Journal of Neurosurgery, 2018, 128, 1123-1132.	1.6	37
26	Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy. JAMA Oncology, 2018, 4, 253.	7.1	76
27	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomyâ€"Reply. JAMA Oncology, 2018, 4, 1620.	7.1	0
28	HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. Oral Oncology, 2018, 86, 69-74.	1.5	4
29	Safety of combining radiotherapy with immune-checkpoint inhibition. Nature Reviews Clinical Oncology, 2018, 15, 477-494.	27.6	208
30	Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis Journal of Clinical Oncology, 2018, 36, 24-24.	1.6	0
31	Immune-related adverse events (IRAEs) in metastatic lung cancer patients receiving PD-1/PD-L1 inhibitors and thoracic radiotherapy Journal of Clinical Oncology, 2017, 35, 9079-9079.	1.6	2
32	The role of radiotherapy in the management of high-grade meningiomas. Chinese Clinical Oncology, 2017, 6, S5-S5.	1.2	25
33	The promise of circulating tumor cells for precision cancer therapy. Biomarkers in Medicine, 2016, 10, 1269-1285.	1.4	11
34	Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro-Oncology, 2016, 18, 863-872.	1.2	91
35	Histone H4 tail mediates allosteric regulation of nucleosome remodelling by linker DNA. Nature, 2014, 512, 213-217.	27.8	78
36	ISWI Remodelers Slide Nucleosomes with Coordinated Multi-Base-Pair Entry Steps and Single-Base-Pair Exit Steps. Cell, 2013, 152, 442-452.	28.9	150

3

#	Article	IF	CITATIONS
37	Droplet networks with incorporated protein diodes show collective properties. Nature Nanotechnology, 2009, 4, 437-440.	31.5	210
38	Droplet interface bilayers. Molecular BioSystems, 2008, 4, 1191.	2.9	411
39	Asymmetric Droplet Interface Bilayers. Journal of the American Chemical Society, 2008, 130, 5878-5879.	13.7	195
40	Screening Blockers Against a Potassium Channel with a Droplet Interface Bilayer Array. Journal of the American Chemical Society, 2008, 130, 15543-15548.	13.7	139
41	Electrical Behavior of Droplet Interface Bilayer Networks:  Experimental Analysis and Modeling. Journal of the American Chemical Society, 2007, 129, 11854-11864.	13.7	98
42	Epi-illumination through the microscope objective applied to darkfield imaging and microspectroscopy of nanoparticle interaction with cells in culture. Optics Express, 2006, 14, 6535.	3.4	40